Lenercept evaluated in phase II for sepsis/septic shock; development for RA halted Oct. 15, 1997 No Comments
KRM-1648: a rifamycin derivative active against H. pylori and Mycobacterium spp. Oct. 15, 1997 No Comments
RSS